查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
NPS+(美國)-瀰漫大B細胞淋巴瘤
市場調查報告書
商品編碼
1789647

NPS+(美國)-瀰漫大B細胞淋巴瘤

NPS+ (US) - Diffuse Large B-Cell Lymphoma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告探討了瀰漫大B細胞淋巴瘤 (DLBCL) 治療領域的競爭格局，並運用 NPS+ 框架對品牌健康度、忠誠度和處方行為進行了深入分析。報告檢視了醫師如何評估領先品牌、滿意度和轉換推動因素，以及最能引起共鳴的訊息。研究結果有助於揭示擁護者和流失擁護者對品牌的看法、影響處方價值的因素，以及增強市場地位的機會。

關鍵問題解答

  • 1.各品牌 NPS 評分比較
  • 2.醫師對特定品牌的忠誠度如何？
  • 3.哪些品牌訊息能引起醫師的共鳴？
  • 4.影響醫師選擇的關鍵因素有哪些？
  • 5.主要品牌的市佔率
  • 6.主要品牌與競爭對手的比較
  • 7.因品牌滿意度低而可能轉換的品牌

主要品牌

  • Adcetris (brentuximab vedotin)
  • Brayangi (lisocabtagene maraleucel)
  • Columbi (glofitamab)
  • Epkinly/Tepkinly (依普利他單抗)
  • Kymriah (tisagenlecleucel)
  • Monjuvi/Minjuvi (他法西他單抗)
  • Porivee (polatuzumab vedotin)
  • Xpovio (serinexol)
  • Yescarta (axicabtagene ciloleucel)
  • Jinronta (loncustuximab tesirin)

方法論：

First View 報告是基於對透過 LiMATM 選出的醫生進行的定量調查得出。 LiMATM 是全球最大的醫生名錄，已確認超過 300 萬名醫生。每位醫生均根據嚴格的篩選標準精心挑選，以確保收集到的見解具有相關性和可靠性，反映頂尖醫療專業人士的真實意見和經驗。調查結果以易於理解的圖表形式呈現，方便您快速理解和分析數據。憑藉 LiMATM 的廣泛覆蓋範圍和精準度，FirstView 報告提供無與倫比的數據驅動洞察，指導策略規劃，幫助您在快速發展的醫療保健領域保持領先地位。

我們的報告有何獨特之處？

FirstView 報告是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入、可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助您掌握新興趨勢，有​​效應對複雜課題。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，我們的報告可提供您所需的準確性和可靠性。獨家訪問獨家訪談和數據，以及持續的市場監測，確保您全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使您能夠做出更明智的、數據驅動的決策，並在快速變化的行業中保持競爭力。

簡介目錄

This report explores the competitive landscape for diffuse large B-cell lymphoma (DLBCL) therapies, providing a detailed analysis of brand health, loyalty, and prescribing behaviors through the NPS+ framework. It examines how physicians rate leading brands, the factors driving satisfaction and switching, and the messages that resonate most. The findings help clarify how brands are perceived by Promoters and Detractors, what influences prescribing value, and where opportunities exist to strengthen market position.

Key Questions Answered:

  • 1. How do NPS scores by brand compare?
  • 2. How loyal are physicians to specific brands?
  • 3. What brand messages resonate with physicians?
  • 4. What are the key factors driving physician choice?
  • 5. What is the market share of leading brands?
  • 6. How does each of the leading brands compare to its competitors?
  • 7. Which brands are vulnerable to switching due to low brand satisfaction?

Key Brands:

  • Adcetris (brentuximab vedotin)
  • Breyanzi (lisocabtagene maraleucel)
  • Columvi (glofitamab)
  • Epkinly/Tepkinly (epcoritamab)
  • Kymriah (tisagenlecleucel)
  • Monjuvi/Minjuvi (tafasitamab)
  • Polivy (polatuzumab vedotin)
  • Xpovio (selinexor)
  • Yescarta (axicabtagene ciloleucel)
  • Zynlonta (loncastuximab tesirine)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.